Your browser doesn't support javascript.
loading
Reduning Injection versus Neuraminidase Inhibitors in the Treatment of Influenza: A Systematic Review and Meta-Analysis.
Zhao, Guo-Zhen; Li, Bo; Wang, Ya-Fan; Guo, Shi-Qi; Du, Yuan; Ma, Qiu-Xiao; Guo, Yu-Hong; Liu, Qing-Quan.
Afiliación
  • Zhao GZ; School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Li B; Department of Emergency, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
  • Wang YF; Beijing Evidence-Based Chinese Medicine Center, Beijing, 100010, China.
  • Guo SQ; Department of Emergency, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
  • Du Y; Beijing Evidence-Based Chinese Medicine Center, Beijing, 100010, China.
  • Ma QX; Beijing Institute of Chinese Medicine, Beijing, 100010, China.
  • Guo YH; Department of Emergency, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
  • Liu QQ; School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China.
Chin J Integr Med ; 28(11): 1023-1031, 2022 Nov.
Article en En | MEDLINE | ID: mdl-35508864
ABSTRACT

OBJECTIVE:

To perform a systematic review to assess the effectiveness and safety of Reduning Injection versus neuraminidase inhibitors in treatment of influenza.

METHODS:

The MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Bio-medical Literature and Retrieval System (Sinomed), China National Knowledge Infrastructure Database (CNKI), China Science and Technology Journal Database (VIP), Wanfang Data Knowledge Service Platform and ClinicalTrails.gov were systematically searched from inception dates to May 2021 for randomized controlled trials (RCTs) exploring Reduning Injection alone or in combination with neuraminidase inhibitors in patients with influenza. Statistical analysis was performed using RevMan 5.4 and Stata 15.1. The qualities of the involved studies were assessed by the risk of bias according to the Cochrane handbook. The evidence quality of each outcome was evaluated by GRADEpro GDT.

RESULTS:

Twelve trials with 1,460 patients were included. The included studies had a certain unclear or high risk of bias. Reduning Injection appeared to be more effective in shortening the fever clearance time (MD -16.20 h, 95% CI -19.40 to -12.99, 7 trials, 814 patients, I2=94%, very low certainty), fever alleviation time (MD -4.09 h, 95% CI -4.22 to -3.96, 3 trials, 366 patients, I2=0%, low certainty), cough alleviation time (MD -21.34 h, 95% CI -41.56 to -1.11, 2 trials, 228 patients, I2=89%, very low certainty), fatigue alleviation time (MD -31.83 h, 95% CI -36.88 to -26.77, 2 trials, 270 patients, I2=0%, low certainty), sore throat alleviation time (MD -28.66 h, 95% CI -32.23 to -25.10, 1 trial, 150 patients, low certainty), and improving the total effective rate (RR 1.15, 95% CI 1.06 to 1.25, 10 trials, 1,074 patients, I2=76%, very low certainty). Besides, Reduning Injection seemed generally safe.

CONCLUSIONS:

This study provided low or very low evidence indicating Reduning Injection may be effective in the treatment of influenza and might be safe. Further rigorously designed studies are needed to confirm the effectiveness and safety of Reduning Injection and support it as a recommendation for influenza.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Gripe Humana Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans Idioma: En Revista: Chin J Integr Med Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Gripe Humana Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans Idioma: En Revista: Chin J Integr Med Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2022 Tipo del documento: Article País de afiliación: China